Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a 15-amino-acid chain based on a sequence identified in human gastric juice. The synthesized peptide concentrates that short sequence into a stable, isolatable form for research, distinct from the naturally occurring protective compound it was derived from. BPC-157 is supplied as either a free base or an acetate salt; product formulation should be confirmed when comparing research findings across sources, since the two are different active ingredients.
Most published BPC-157 findings come from cell and animal models. Human research is at an early stage, and the distinction matters for interpreting the literature honestly:
| Research area | Laboratory and animal findings | Human research |
|---|---|---|
| Tendon, ligament, and muscle | Repair-related changes across multiple animal injury models | A controlled Phase 2 study in adults with acute hamstring strains is recruiting; results are not yet posted |
| Gastrointestinal tract | Extensive animal data on ulcers, fistula healing, and inflammatory injury | A related formulation has been evaluated in inflammatory bowel disease trials; direct human data for the isolated peptide remains limited |
| Safety | Multiple animal toxicity studies across several species | A published pilot report followed two adults receiving intravenous BPC-157, an early data point, not a broad human safety profile |
BPC-157 has been investigated across multiple proposed biological pathways associated with gastrointestinal protection, vascular recruitment, tissue repair, and nervous system research.
Research has also examined BPC-157 in tendon models and in vitro tendocyte studies. However, the available evidence does not support treating any single proposed mechanism as a confirmed explanation for all observed experimental findings.
Mechanistic observations from cellular and animal studies should be distinguished from demonstrated clinical effects in humans.
No standardized dosing protocol exists for BPC-157 outside of individual study designs, and any research protocol, route, or dose is determined solely by the licensed researcher or practitioner and their institution.
Animal and preclinical research has most frequently used subcutaneous or intraperitoneal administration; a pharmacokinetic study in rats and dogs has also examined intravenous and intramuscular dosing. Route affects absorption and exposure to digestive enzymes, so findings from one route should not be assumed to describe another. This reflects historical study design, not a recommended or current protocol.
For labs converting a professional’s own determined research dose into an accurate reconstitution volume, CellGenic’s calculator tool is open to any visitor, with no account required.
A preclinical safety program spanning mice, rats, rabbits, and dogs reported no serious toxicity in single-dose and repeat-dose experiments, one reason BPC-157 is often described as well tolerated in the research literature. This reflects animal findings rather than an established human safety profile. Product quality is a distinct part of the safety picture: strength, purity, sterility, and consistent characterization of the active ingredient can vary significantly between sources. Researchers should establish baseline laboratory values before and during any protocol.
Every CellGenic lot is manufactured under cGMP conditions and undergoes mycoplasma, sterility, identity, and potency testing prior to release. Certificates of Analysis are issued per batch and can be retrieved directly using your batch number.
BPC-157 is frequently studied and supplied alongside TB-500 as a research pairing. BPC-157’s research centers on local, tissue-level effects on angiogenesis, fibroblast activity, and gastrointestinal repair, while TB-500 is studied for broader, systemic cell migration. CellGenic supplies BPC-157 as a standalone research vial, alongside the combined pairing across three formats.
Within CellGenic’s own provider protocols, BPC-157 also appears paired with GHK-Cu and TB-500 for acute soft-tissue research contexts, and layered with GHK-Cu, DSIP, and TB-500 for long-horizon structural repair research.
Become a Provider → A CellGenic specialist will follow up within one business day. Once your account is verified, full pricing and Certificates of Analysis unlock automatically.
These products are intended for laboratory research use only. They are not drugs, foods, cosmetics, or medical treatments and must not be used for any form of human or animal administration. All information provided is for educational and scientific reference only and the products should be handled exclusively by licensed, qualified professionals. Misbranding, misuse, or mislabeling of these products as therapeutic or consumable substances is strictly prohibited by law.
CellGenic ships exclusively to Mexico, Argentina, Colombia, and Perú under local license. Verified-provider-only platform from CellGenic.